These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Heparin-induced thrombocytopenia in critically ill patients. Warkentin TE Crit Care Clin; 2011 Oct; 27(4):805-23, v. PubMed ID: 22082515 [TBL] [Abstract][Full Text] [Related]
8. Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. Lauzier F; Arnold DM; Rabbat C; Heels-Ansdell D; Zarychanski R; Dodek P; Ashley BJ; Albert M; Khwaja K; Ostermann M; Skrobik Y; Fowler R; McIntyre L; Nates JL; Karachi T; Lopes RD; Zytaruk N; Finfer S; Crowther M; Cook D Intensive Care Med; 2013 Dec; 39(12):2135-43. PubMed ID: 23942857 [TBL] [Abstract][Full Text] [Related]
9. Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin. ten Berg MJ; van den Bemt PM; Huisman A; Schobben AF; Egberts TC; van Solinge WW Ann Pharmacother; 2009 Sep; 43(9):1405-12. PubMed ID: 19690229 [TBL] [Abstract][Full Text] [Related]
10. Dalteparin vs warfarin in hip arthroplasty patients. Bajjoka AE Arch Intern Med; 2001 Mar; 161(5):776-8. PubMed ID: 11231726 [No Abstract] [Full Text] [Related]
11. Current practice of thromboprophylaxis in the burn population: a survey study of 84 US burn centers. Ferguson RE; Critchfield A; Leclaire A; Ajkay N; Vasconez HC Burns; 2005 Dec; 31(8):964-6. PubMed ID: 16269216 [TBL] [Abstract][Full Text] [Related]
13. Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment. Tvito A; Bakchoul T; Rowe JM; Greinacher A; Ganzel C Am J Hematol; 2015 Jul; 90(7):675-8. PubMed ID: 25683147 [No Abstract] [Full Text] [Related]
14. [Economic analysis of dalteparin use in knee surgery at Instituto Mexicano del Seguro Social]. Arreola-Ornelas H; Rosado-Buzzo A; García-Mollinedo L; Dorantes Aguilar J; Muciño-Ortega E; Mould-Quevedo JF Cir Cir; 2012; 80(5):411-8. PubMed ID: 23351443 [TBL] [Abstract][Full Text] [Related]
15. Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed? Prescrire Int; 2000 Feb; 9(45):197-8. PubMed ID: 11503794 [TBL] [Abstract][Full Text] [Related]
16. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M; N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587 [TBL] [Abstract][Full Text] [Related]
17. Risk assessment and prophylaxis of venous thromboembolism in acutely and/or critically ill patients. Davidson BL Haemostasis; 2000; 30 Suppl 2():77-81; discussion 63. PubMed ID: 11251346 [TBL] [Abstract][Full Text] [Related]
18. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ; Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368 [TBL] [Abstract][Full Text] [Related]
19. Think of HIT when thrombosis follows heparin. Warkentin TE Chest; 2006 Sep; 130(3):631-2. PubMed ID: 16963651 [No Abstract] [Full Text] [Related]
20. [Thrombocytopenia can be HIT. Heparin treatment can cause low life-threatening thrombocyte levels]. Själander A; Johansson L; Hillarp A; Bergqvist D; Tengborn L; Svensson P Lakartidningen; 2009 Mar 4-10; 106(10):682-5. PubMed ID: 19418688 [No Abstract] [Full Text] [Related] [Next] [New Search]